合并糖尿病的毒性甲状腺肿患者内分泌疾病的治疗

Treatment of Endocrine Diseases in Patients with Diabetic Toxic Goiter

目的探究合并糖尿病的毒性甲状腺肿患者内分泌疾病的临床用药及治疗效果。方法将该院于2018年8月—2019年7月收治的50例毒性甲状腺肿合并糖尿病伴有内分泌眼病患者随机分为治疗组和对照组,各25例,分别加用环磷酰胺联合甲强龙治疗和给予常规药物治疗,比较两组临床治疗效果。结果治疗组治疗总有效率(96.00%)高于对照组(80.00%),比较差异有统计学意义(P<0.05)。治疗后,治疗组患者空腹血糖水平为(5.1±0.4)mmol/L,对照组为(6.7±0.7)mmol/L,治疗组低于对照组,差异有统计学意义(P<0.05)。结论在常规用药基础联合磷酰胺联合甲强龙冲击治疗毒性甲状腺肿合并糖尿病伴有内分泌眼病,疗效显著,安全性高。

Objective To explore the clinical application and therapeutic effect of endocrine diseases in patients with toxic goiter with diabetes.Methods Fifty patients with toxic goiter complicated with diabetes and endocrine eye disease from August 2019 to July 2019 in the hospital were randomly divided into a treatment group and a control group,with 25 cases in each group.They were treated with cyclophosphamide combined with methylprednisolone and given conventional drugs.The two groups were compared for clinical treatment effect.Results The total effective rate(96.00%)in the treatment group was higher than that in the control group(80.00%),and the difference was statistically significant(P<0.05).After treatment,the fasting blood glucose level in the treatment group was(5.1±0.4)mmol/L,and the control group was(6.7±0.7)mmol/L.The treatment group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion Conventional medication based on combined use of phosphoramide and methylprednisolone in the treatment of toxic goiter with diabetes associated with endocrine eye disease has significant efficacy and high safety.